Megace (Megestrol Acetate)

Megestrol acetate is a synthetic progestogen that binds to progesterone receptors, influencing gene expression that slows tumor growth in hormone‑dependent cancers. It also exerts glucocorticoid‑like activity in the hypothalamus, enhancing appetite and reducing catabolic processes that lead to weight loss.

The appropriate dose of Megace is individualized by the prescribing clinician based on the patient’s condition, severity of cachexia or cancer stage, and response to therapy. No fixed regimen is provided here; dosing decisions are made by qualified healthcare professionals.

Safety of Megace in pregnancy and lactation has not been established. Because potential risks to the fetus or infant are unknown, the drug is generally avoided in pregnant or nursing women unless the benefits clearly outweigh the risks and are approved by a physician.

To order Megace, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other appetite stimulants such as corticosteroids or mirtazapine, Megace offers both appetite‑enhancing and antineoplastic benefits, making it useful in cancer‑related cachexia. However, its hormonal activity can lead to unique side‑effects like thromboembolism, which are less common with non‑hormonal agents.

Megace tablets should be stored at ambient temperature, below 25 °C, in the original container to protect from moisture. Keep the product out of direct sunlight and away from sources of heat. Do not use if the packaging is damaged or the tablets appear discoloured.

Megace is administered orally, typically as a tablet taken with or without food as directed by the prescriber. Patients should follow the dosing schedule provided by their healthcare professional and should not alter the frequency or amount without medical advice.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, adrenal suppression leading to cortisol deficiency, severe hyperglycemia, and rare allergic reactions like anaphylaxis. Patients should be monitored closely for signs of these conditions, especially during long‑term therapy.

Megace is contraindicated in individuals with known hypersensitivity to megestrol acetate or any excipients, those with active thromboembolic disease, uncontrolled diabetes, or severe hepatic impairment. Caution is also advised for patients with a history of cardiovascular disease or adrenal insufficiency.